<DOC>
	<DOC>NCT02235480</DOC>
	<brief_summary>The aim of this study is to determine the efficacy and safety of topical application of the gel compared to placebo in nail psoriasis.</brief_summary>
	<brief_title>Efficacy and Safety of Tazarotene Gel in Nail Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Key inclusion criteria: Mild to moderate nail psoriasis on at least one fingernail Key exclusion criteria: any other skin condition, with a potential to affect the nails or to interfere with evaluation of the disease; history of hypersensitivity to retinoids or to other components of the trial medication topical treatment of nails with antipsoriatics in the 4 weeks preceding the treatment phase; systemic treatment of psoriasis within the three months before the treatment phase of the trial or during the trial intralesional steroid injection before the treatment phase of the trial phototherapy before the treatment phase of the trial; any chronic infection or condition capable of interfering with the conduct of the trial; evidence of drug or alcohol abuse; symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks preceding the treatment phase of the trial; participation in another clinical trial within the last 4 weeks prior to first treatment in this clinical trial; pregnancy or nursing;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>